GlassScriptPhysician profile
David F Cowan
NPI 1689658155
$3,570.76
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $603 · 2021: $905 · 2022: $966 · 2023: $362 · 2024: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $522.85 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $479.41 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $327.27 | 2019-2023 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $255.11 | 2019-2023 | Farxiga |
| Amgen INC. | $232.21 | 2019-2024 | Evenity, Prolia, Repatha |
| Pfizer INC. | $162.07 | 2019-2023 | |
| Esperion Therapeutics, INC. | $138.18 | 2020-2023 | Nexletol |
| Daiichi Sankyo INC. | $129.95 | 2019-2022 | |
| Lilly USA, LLC | $125.55 | 2019-2023 | Mounjaro |
| Exact Sciences Corporation | $125.25 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $121.97 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $118.97 | 2021 | |
| Aytu Biopharma, INC. | $71.59 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.48 | 2019-2022 | |
| Amarin Pharma, INC. | $61.53 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.